Paradigm Biopharma – executive interview

Paradigm Biopharma is an Australian biotechnology company focused on the development of injectable pentosan polysulfate (iPPS). Its most advanced clinical programme is investigating the drug for the treatment of knee osteoarthritis (kOA), a degenerative disease with significant unmet medical needs. Paradigm’s pivotal Phase III trial, PARA_OA_002, is a multi-centre, two-stage, adaptive, randomised, double-blind, placebo-controlled study to assess iPPS in patients with kOA pain. Management expects stage one to be complete in Q3 CY23, and for stage two to commence with the most effective dose later in H2 CY23. The company is also investigating iPPS as a potential disease-modifying OA drug (DMOAD) in the Phase II trial, PARA_OA_008. An update is expected in H2 CY23, and the company is preparing for discussions with key regulatory agencies to reach an agreement on a potential DMOAD label. In addition, Paradigm is conducting two Phase II trials to investigate iPPS as a treatment of mucopolysaccharidosis types I and VI, and top-line data are expected in Q4 CY23.
In this video, Paul Rennie, CEO, co-founder and chairman, provides background on the company’s addressable (potential) market opportunity and an overview of its clinical pipeline.